ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,267.84
-0.74%
US Tech 100
18,138.40
-0.49%
다우존스 지수
39,065.26
-1.53%
Bitcoin
67,589.89
-2.19%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) 뉴스

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:TNGX
일자시간출처헤드라인심볼기업
2024/05/2322:18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
2024/05/2320:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/05/2320:00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
2024/05/0820:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
2024/05/0820:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/05/0820:00Business WireTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
2024/04/0205:48Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
2024/03/1820:00Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
2024/03/0621:00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
2024/03/0606:47GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:TNGXTango Therapeutics Inc
2024/02/0911:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/02/0911:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/02/0721:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/02/0606:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/02/0606:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/01/3121:00GlobeNewswire Inc.Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TNGXTango Therapeutics Inc
2024/01/0606:05GlobeNewswire Inc.Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
2024/01/0416:47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
2024/01/0321:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
2023/11/1321:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
2023/11/0821:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
2023/11/0821:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2023/11/0821:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
2023/11/0721:00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
2023/11/0305:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2023/10/1906:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
2023/09/1820:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
2023/09/1213:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
2023/09/0620:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
2023/09/0520:00GlobeNewswire Inc.Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TNGXTango Therapeutics Inc
 검색 관련기사 보기:NASDAQ:TNGX

최근 히스토리

CCOM
SILVER
SILVER
CCOM
US30
US 30
NYSE
KO
Coca Cola
FX
USDGBP
US Dollar vs Sterling
NASDAQ
GOOGL
Alphabet
NYSE
AXP
American Express
CCOM
US100
US Tech 100
AMEX
XLV
Health Care Select Sector
FX
USDJPY
US Dollar vs Yen
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
PM
XAUUSD
Gold vs US Dollar
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유